Avstera is a Pennsylvania based biotech developing novel, best-in-class highly selective oral HDAC6 inhibitors targeting a broad range of diseases including obesity/cardiometabolic, and other related indications. Lead is Phase I ready with several candidates approaching IND.
Address
PhiladelphiaPennsylvania
United States
